clinical trial · NCT06182696
OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM
OriCell Therapeutics Co., Ltd.·phase2·recruiting·n = 83
Relapsed and/or Refractory Multiple MyelomaOriCAR-017
brief summary
An open label, dose exploratory clinical study to evaluate the safety, efficacy, and pharmacokinetics of OriCAR-017 in R/RMM
started
Oct 26, 2023
primary completion
Nov 30, 2026
completion
Aug 31, 2028
last updated
May 31, 2024
detailed description
This is a Phase I and Phase II, open-label, multi-center study to assess the safety, pharmacokinetics, and efficacy of GPRC5D directed chimeric antigen receptor modified T cells injection (OriCAR-017) in n patients with relapsed and/or refractory multiplemyeloma (R/RMM).
official title
An Open Label,Multi-center Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Autologous T Cell Injection Targeting GPRC5D OriCAR-017 in Patients With Relapsed and/or Refractory Multiplemyeloma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol